[Treatment with recombinant parathyroid hormone of advanced osteoporosis--series of cases].
Osteoporosis is a systemic skeletal disorder characterized by impaired bone strength, leading to an increased risk of fracture. Patients with severe osteoporosis and multiple vertebral fractures are particularly at risk for subsequent osteoporotic fractures independently of antiresorptive therapy. The effective treatment of osteoporosis should prevent fractures through normalization of bone mass and improving bone microarchitecture. Recombinant human parathyroid hormone (teriparatide) is an anabolic (bone forming) agent. The aim of this study was to describe the results of treatment with teriparatide (Forsteo) of three patients with severe osteoporosis. Teriparatide has proved to be effective in preventing bone loss. New osteoporotic fracture has not occurred in two patients. Treatment with teriparatide was safe and well tolerated.
Katedra i Klinika Nefrologii, Endokrynologii i Chorób Przemiany Materii, Slaski Uniwersytet Medyczny w Katowicach.
Katarzyna
K
Skiba
Marcin
M
Adamczak
Andrzej
A
Wiecek
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D019379:Teriparatide / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D019379:Teriparatide